INTRODUCTION
Cystic fibrosis is one of the most common genetic diseases among Caucasians due to its prevalence. There are approximately 1,200 diagnosed CF patients in Poland. However, it is estimated that the number of patients is greater, because many patients with similar symptoms are treated for other diseases. Modern methods of molecular diagnostics and treatment of diseases allow patients to prolong life and give a chance to improve its quality. In order to apply the appropriate treatment, the genetic basis of the disease should first be known.
The development of diagnostic techniques has made it possible to identify many genetic diseases that are conditioned by chromosomal aberrations or epigenetic changes. Depending on the changes occurring in the genome, various molecular techniques are used to identify genetic diseases.
Developing a diagnostic test to identify
Among the molecular biology techniques most commonly used in clinical diagnosis include: polymerase chain reaction (PCR), gel electrophoresis and its varieties, cloning of DNA fragments, DNA sequencing, Southern blotting, hybridization, Northern blot, in situ hybridization, FISH (fluorescent in situ hybridization) and DNA microarrays.
METHODS AND IDENTIFICATION OF THE SELECTED MUTATION OF THE CFTR GENE
The study was conducted on biological material obtained from 18 patients with cystic fibrosis. The genetic test was carried out with valid consent expressed by the Bioethical Commission. Each patient received an informed consent to participate in the study.
Cystic fibrosis is one of the most common genetic diseases among Caucasians due to its prevalence. Modern methods of molecular diagnostics and treatment of the disease allow to prolong the life of patients. In order to apply the appropriate treatment, the genetic basis of this disease should, however, first be known. The most common and the most severe mutation present in the CFTR gene (60-70% of cases) takes the form of an allele. This is responsible for the deletion of phenylalanine in position 508 (Δ508) of the CFTR protein. Determination of mutations in the CFTR gene using molecular techniques makes it possible to identify the causes of the disease in people who do not show the characteristic symptoms of cystic fibrosis.
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The aim of the work was to develop a diagnostic test for the identification of a selected mutation within the CFTR gene that determines the onset of cystic fibrosis.
The biological material was collected in the form of a cytological smear from the oral cavity. DNA isolation was performed using isolation kits. The assessment of the presence of the ΔF508 mutation in the CFTR gene was performed using two methods: 1. Polymerase chain reaction (PCR). 2. DNA sequencing.
A cytological swab was collected by using sterile swabs. The swab was obtained from patients in duplicate. DNA isolation was carried out according to the original protocol.
The PCR reaction was carried out using proprietary designed oligonucleotides. 3. Three variants of the starters have been designed: • 1 pair -oligonucleotides to obtain amplicon in patients with at least one normal allele within the CFTR gene, i.e. lacking the CTT deletion characteristic of the ΔF508 mutation of the primers: MUKO1L-MUKO1R and MUKO1L-MUKO2R, • 2 pair -oligonucleotides to obtain amplicon in patients with at least one abnormal allele within the CFTR gene, i.e. a CTT deletion characteristic of the ΔF508 mutation of the primer names: MUKO1L-MUKO3R and MUKO1L-MUKO4R, • 3 pair -oligonucleotides to obtain an amplicon containing the site of the ΔF508 mutation in the CFTR gene to know the DNA sequence of this genomic region›s starter names: MUKO5L-MUKO5R. 4. The primers were designed in the Primer3 Inpvt program (version 0.4.0). People with allele lacking CTT deletion -2 alternative MUKO1L starter pairs were designed -MUKO1R and MUKO1L-MUKO2R.
People with CTT deletion (ΔF508 mutation) -2 alternative MUKO1L starter pairs were designed -MUKO3R and MUKO1L-MUKO4R.
Primers that allow the amplification of the gene section in which the mutation is present -the MUKO5L primer pair-MUKO5R.
Detection of the resulting PCR product was obtained by electrophoresis in a 1.5% agarose gel. The next stage of this study was the sequencing of nucleic acids.
RESULTS AND CONCLUSIONS
In this work, three exemplary fluorograms obtained by DNA sequencing were presented: Figure 1 presents heterozygote with deletion and without CTT deletion (14), 1. Among the designed methods, DNA sequencing with a pair of MUKO5L and MUKO5R primers made it possible to determine the genotype within exon 10 of the CFTR gene in the largest number of patients. 2. Using the PCR method, we managed to determine the genotype in less than half of the analyzed samples. 3. Among the two primer pairs analyzed, which were designed to amplify the ΔF508 DNA fragment within the CFTR gene, better results were obtained with the MUKO1L and MUKO2R oligonucleotides. 4. Among the two primer pairs analyzed, which were designed to amplify the DNA fragment lacking the ΔF508 mutation within the CFTR gene, better results were obtained using the MUKO1L and MUKO4R oligonucleotides.
The results obtained indicate the benefits of using two
methods of analysis of the ΔF508 mutation in the CFTR gene simultaneously. However, the DNA sequencing method should be considered as a reference.
DISCUSSION
The incidence of CFTR gene mutation in Caucasians is 1/25. The most frequent finding is the F508del mutation in which a deletion of three nucleotides in exon 10 results in the loss of phenylalanine at position 508 of the CFTR protein. Most cases of this disease are caused by the F508del mutation in both gene alleles. The presence of the F508del mutation and other mutations (complex heterozygote) is usually the cause of the formation of disorders of varying severity of symptoms. It is dependent on the effect of particular mutations on the structure and function of the chloride channel and the sum of the effects caused by mutations. In the Polish population, in addition to the F508del mutation, the following mutations are found more often than 1% of patients with cystic fibrosis: 3949 + 10kbC > T (2.6%), G542X (2.5%), N1303K (1.7%), 1717 -IG > A (1.7%), R553X (1%), CFTR dele2, 3 (21kb) (2%) [1, 2] . Stężowska-Kubiak [3] reports that the ΔF508 mutation occurs on 56.3% of alleles in people with CF symptoms [3] . Among these patients, the majority were F508del/F508del homozygotes, and the genotype including ΔF508del and known or unknown mutation occurred in 48.7% of all patients [4] [5] [6] . However, data on the presence of the ΔF508 mutation obtained in this study show the presence of the F508del/F508del genotype in only 27.7% of the population studied. In the conducted genetic study based on the sequencing technique, it was found that 8 patients with cystic fibrosis are heterozygotes with at least 1 allele with CTT deletion and 2 allele lacking CTT deletion.
The frequency of occurrence of the tested ΔF508 mutation in this study differs from the frequency of its occurrence in the Polish population. This discrepancy is probably due to the smaller number of patients tested for the detection of the ΔF508 mutation in the CFTR gene. Bal et al. [4] determined the incidence of the ΔF508 mutation in 84 Polish patients as 47.2%. In the paper by Witta et al. [6] the incidence of the ΔF508 mutation in the group of 617 patients was higher than in the studies of Bala et al., here -53.9%. In Pogorzelski's [5] study, the incidence of the ΔF508 mutation was comparable to that of Witt [6] and amounted to 56.4%.
Bobadilla et al. [7] situate the population of Poland in a population group characterized by a high frequency of the ΔF508 mutation. This group also includes countries such as Germany (71.8%), Belarus (61.2%), the Czech Republic (70%) and Belgium (75.1%). In the French registry, 43.1% of all patients turned out to be ΔF508 homozygotes, and 36% had the F508del genotype or other known mutation [8] .
In the United Kingdom, from 5701 patients -54.3% were ΔF508 homozygotes, and in total, this mutation occurred in 92% of all respondents [9] . According to Irish data, ΔF508 homozygotes represent 64% of the studied population, and 94% of all patients have at least one allele with this mutation [10] . Similarly in Australia -94% of the population have at least one allele with the ΔF508 mutation, and 51.4% are homozygous for the molecular defect [11] . Among 3084 patients from Canada -49.2% have the F508del/F508del genotype, and 39.1% of all patients have at least one allele with this mutation [12] . The German report from 2009 verifies the percentage of the ΔF508 mutation presented in the work of Bobadilla et al. [7] -it occurred in a total of 65.7% of all patients with at least one allele with this mutation, and 46.9% of all patients who turned out to be homozygotes [13] .
In this work, during the study, a combination of five primer pairs (MUKO1L/MUKO1R, MUKO1L/MUKO2R, MUKO1L/MUKO3R, MUKO1L/MUKO4R, MUKO5L/ MUKO5R) was used. The MUKO1L/MUKO1R and MUKO1L/MUKO2R primers were designed to obtain the amplicon in the presence of at least one allele lacking CTT deletion in the CFTR gene. In turn, the MUKO1L/MUKO3R and MUKO1L/MUKO4R primers were designed to obtain the amplicon in the presence of at least one allele with the CTT deletion in the CFTR gene. Finally, the MUKO5L/ MUKO5R primers aimed at amplifying the gene section in which the CTT deletion is present.
Among the latest research, the use of preimplantation diagnosis of cystic fibrosis should be noted. Preimplantation diagnostics is a method that allows genetic analysis of oocytes before or after fertilization or embryos before introducing them into the uterus of the future mother [14] . This diagnosis allows the analysis of the more than 30 mutations in the CFTR gene most frequently occurring in Europe [15] . Due to the high heterogeneity of mutations in the CFTR gene, in recent years, the identification of individual mutations has been supplemented with the analysis of highly polymorphic markers surrounding the CFTR gene [16] or intra gene [17] .
Moutou et al. [17] proposed the use of two polymorphic intra-gene markers (IVS8CA and IVS17bCA) in combination with the identification of the F508del mutation. Goossens et al. additionally used an intra-gene marker IVS17bTA and four polymorphic markers that surround the gene (D7S490, D7S486, D7S480 and D7S523) [18] . This approach allows to propose a preimplantation diagnosis of cystic fibrosis in people with unknown or very rare mutations.
